血小板衍生TGF-β1诱导免疫性血小板减少症中髓源性抑制细胞的功能重编程
该研究在免疫性血小板减少症(ITP)小鼠模型中发现,血小板α颗粒富含的TGF-β1通过TGF-β/Smad通路诱导髓源性抑制细胞(MDSC)扩增和功能重编程;血小板TGF-β1缺陷小鼠中TPO受体激动剂诱导的MDSC扩增和抑制能力增强被消除;回顾性数据显示ITP患者达到完全血小板缓解者长期结局优于仅部分缓解者。
要点
- TPO受体激动剂通过血小板TGF-β1经TGF-β/Smad通路增强MDSC抑制活性。
- 血小板TGF-β1缺陷小鼠中TPO-RA诱导的MDSC扩增和抑制能力增强被消除。
- ITP患者达到完全血小板缓解者长期结局优于仅部分缓解者。
核心结论
- 血小板TGF-β1通过TGF-β/Smad通路诱导MDSC扩增和功能重编程。
- 血小板恢复不仅是治疗反应终点,也为免疫介导的血小板减少症免疫稳态铺平道路。
研究设计与样本
- 将抗CD61免疫致敏的脾细胞转移至严重联合免疫缺陷小鼠,建立活动性ITP小鼠模型。
- 采用转录组分析、Smad2/3敲低和血小板TGF-β1缺陷小鼠进行机制研究。
- 回顾性分析ITP患者达到完全血小板缓解与仅部分缓解的长期结局。
主要发现
- TPO-RA通过阻滞浆细胞分化、降低细胞毒性T细胞Fas配体表达和再平衡T细胞亚群增强MDSC抑制活性。
- 转录组分析证实TGF-β/Smad通路参与TPO-RA纠正的MDSC,Smad2/3敲低可抵消该效应。
- 血小板TGF-β1缺陷小鼠中TPO-RA诱导的MDSC扩增和抑制能力增强被消除。
- 回顾性数据显示ITP患者达到完全血小板缓解者长期结局优于仅达到部分缓解者。
临床怎么用
- 作者认为血小板恢复不仅是治疗反应终点,也为免疫介导的血小板减少症免疫稳态铺平道路。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platelet α-granules are rich in transforming growth factor β1 (TGF-β1), which is associated with myeloid-derived suppressor cell (MDSC) biology. Responders to thrombopoietin receptor agonists (TPO-RAs) revealed a parallel increase in the number of both platelets and MDSCs. Here, anti-CD61 immune-sensitized splenocytes were transferred into severe combined immunodeficient mice to establish an active murine model of immune thrombocytopenia (ITP). Subsequently, we demonstrated that TPO-RAs augmented the inhibitory activities of MDSCs by arresting plasma cells differentiation, reducing Fas ligand expression on cytotoxic T cells, and rebalancing T-cell subsets. Mechanistically, transcriptome analysis confirmed the participation of TGF-β/Smad pathways in TPO-RA-corrected MDSCs, which was offset by Smad2/3 knockdown. In platelet TGF-β1-deficient mice, TPO-RA-induced amplification and enhanced suppressive capacity of MDSCs was waived. Furthermore, our retrospective data revealed that patients with ITP achieving complete platelet response showed superior long-term outcomes compared with those who only reach partial response. In conclusion, we demonstrate that platelet TGF-β1 induces the expansion and functional reprogramming of MDSCs via the TGF-β/Smad pathway. These data indicate that platelet recovery not only serves as an end point of treatment response but also paves the way for immune homeostasis in immune-mediated thrombocytopenia.
引用
- Wang L, Wang H, Zhu M, et al. Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia. Blood. 2024. PMID: 38574321. doi:10.1182/blood.2023022738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。